ArticleAnnals of human genetics2025
The Fortunes of Genomic Medicine: A Quarter Century of Promise.
Article in Annals of human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Environmentally responsible human genomic data governance: points for consideration.NPJ genomic medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundThe culmination of the Human Genome Project in the early 2000s came wreathed in promises of a revolution in medicine and healthcare. The ensuing quarter century has seen remarkable growth in genomic medicine, as well as notable shifts in the promissory rhetoric that accompanies it.
methodsThis essay draws on a contextualist close reading of scientific and policy literature published from the 1990s to the present, using thematic and narrative analysis informed by perspectives from the sociology of expectations, to examine the role of different kinds of promissory claims in shaping the development of genomic medicine in the UK, and particularly England, over that period.
resultsEarly promises about the medical benefits that will follow from the development of genomic medicine have been scaled back and refocused as the possibilities and limitations of genomic technologies have become apparent; while investment has shifted from basic discovery resources aimed at elucidating the genetics of common disorders to clinical facilities focused on the genomics of rare diseases and cancer. Research in these areas has delivered a range of highly-publicised diagnostic and therapeutic innovations, but so far the benefits to patients have generally been modest or confined to relatively small populations, and come at a high cost, both financial and human. Meanwhile, a rather different set of promises, focused on economic growth through biomedical innovation, has been instrumental in shaping how the field of genomic medicine has developed, especially within the National Health Service. One consequence has been a blurring of the distinction between medical care and biomedical research, with genomic medicine patients and their data increasingly being reframed as an economic resource for purposes of commercially-driven innovation.
conclusionIn this context, efforts to persuade patients of the personal or public value of research participation, and especially proposals to abandon the principle of clinical non-directiveness in genomic healthcare, raise uncomfortable questions about just whose interests genomic medicine, as currently constituted, is best designed to serve.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.